Two therapeutic targets identified for deadly lung cancer

The vast majority of deadly lung cancer cases (85 percent) are termed non-small-cell lung carcinomas (NSCLCs), which often contain a mutated gene called LKB1. Researchers have now discovered precisely why inactive LKB1 results in cancer development. The surprising results highlight how LBK1 communicates with two enzymes that suppress inflammation in addition to cell growth, to block tumor growth. The findings could lead to new therapies for NSCLC.